Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload

Neurochemistry International

Volumn 49, Issue 6, 2006, Pages 605-609

  Jiang, Hong ^a   Luan, Zhuo ^a   Wang, Jun ^a   Xie, Junxia ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Desferal; Dopaminergic neuron; Iron; Parkinson's disease; Substantia nigra

Indexed keywords

DEFEROXAMINE MESYLATE; DOPAMINE; IRON; IRON CHELATING AGENT; IRON DEXTRAN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD BRAIN BARRIER; CYCLIC POTENTIOMETRY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IRON OVERLOAD; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEFEROXAMINE; DOPAMINE; ELECTRIC STIMULATION; ELECTROCHEMISTRY; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MICROELECTRODES; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TRYPTOPHAN HYDROXYLASE;

EID: 33749506725     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.04.015     Document Type: Article

References (32)

1. Andersen J.K. Iron dysregulation and Parkinson's disease. J. Alzheimers Dis. 6 6 Suppl. (2004) S47-S52
2. Ben-Shachar D., Eshel G., Finberg J.P., and Youdim M.B. The iron chelator desferrrioxamine (Desferal) retards 6-hydroxydopamine induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56 (1991) 1441-1444
3. Ben-Shachar D., Kahana N., Kampel V., Warshawsky A., and Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46 2 (2004) 254-263
4. Berg D., Grote C., Rausch W.D., Maurer M., Wesemann W., Riederer P., and Becker G. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Utrasound Med. Biol. 25 6 (1999) 901-904
5. Dal-Pizzol F., Klamt F., Frota Jr. M.L., Andrades M.E., Caregnato F.F., Vianna M.M., Schroder N., Quevedo J., Izquierdo I., Archer T., and Moreira J.C. Neonatal iron exposure induces oxidative stress in adult Wistar rat. Dev. Brain. Res. 130 1 (2001) 109-114
6. Gal S., Zheng H., Fridkin M., and Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 95 1 (2005) 79-88
7. Galleano M., Aimo L., and Puntarulo S. Ascorbyl radical/ascorbate ratio in plasma from iron overloaded rats as oxidative stress indicator. Toxicol. Lett. 133 2-3 (2002) 193-201
8. Gassen M., and Youdim M.B. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol. Toxicol. 80 4 (1997) 159-166
9. Glinka Y., Tipton K.F., and Youdim M.B. Nature of inhibition of mitochondrial respiratory complex 1 by 6-hydroxydopamine. J. Neurochem. 66 (1996) 2004-2010
10. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S26-S36
11. Jiang H., Chen W.F., and Xie J.X. Relationship between dopamine and iron contents in the brain of Parkinsonian rats. Acta Physiol. Sinica 53 4 (2001) 334-338
12. Jiang H., Xie J.X., and Qian Z.M. The increased DMT1 expression and iron content in mptp-treated c57bl/6 mice. Acta Physiol. Sinica 55 5 (2003) 571-576
13. Kaur D., and Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease?. Ageing Res. Rev. 3 3 (2004) 327-343
14. Lehermitte J., Kraus W.M., and McAlpine M.A. On the occurrence of abnormal deposits of iron in the brain in Parkinsonism with special reference to its localization. J. Neurol. Psychopathol. 5 (1924) 195-208
15. Mamula P., Piccoli D.A., Peck S.N., Markowitz J.E., and Baldassano R.N. Total dose intravenous infusion of dextran for iron-deficiency anemia in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 34 (2002) 286-290
16. Meissner W., Hill M.P., Tison F., Gross C.E., and Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol. Sci. 25 5 (2004) 249-253
17. Minotti G., and Aust S.D. The requirement for iron(III) in the initiation of lipid peroxidation by iron(II) and hydrogen peroxide. J. Biol. Chem. 262 (1987) 1098-1104
18. Oberhauser E., Weinstein V., and Asenjo A. Iron concentration basal ganglia and cerebral cortex obtained by overloading rabbits and monkeys with iron dextran. J. Neurosurg. 32 6 (1970) 669-677
19. Paxinos, G., Watson, C., 1986. The rat brain in stereotaxic coordinates. Academic Press, London, 1-104.
20. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth Jr. W.T., Swanson P.D., and Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60 11 (2003) 1761-1766
21. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., and Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52 2 (1989) 515-520
22. Sangchot P., Sharma S., Chetsawang B., Porter J., Govitrapong P., and Ebadi M. Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev. Neurosci. 24 2-3 (2002) 143-153
23. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., and Youdim M.B. Increased iron(III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neurol. Transm. 74 3 (1988) 199-205
24. Stamford J.A. Fast cyclic voltammetry: measuring transmitter release in 'real time'. J. Neurosci. Methods 34 1-3 (1990) 67-72
25. Wang J., Jiang H., and Xie J.X. Time dependent effects of 6-OHDA lesions on iron level and neuronal loss in rat nigrostriatal system. Neurochem. Res. 29 12 (2004) 2239-2243
26. Xie J.X., Jiang H., Chen W.F., and Qian Z.M. Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease. Exp. Neurol. 182 2 (2003) 483-489
27. Xie J.X., and Tang M. Effects of electrical stimulation of the dopaminergic nerve fiber or nerve terminal on striatal dopamine release in the rat. Chin. J. Neurosci. 15 1 (1999) 20-26
28. Youdim M.B., Ben-Shachar D., and Riederer P. The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson' disease. J. Neural. Transm. 32 Suppl. (1990) 239-248
29. Youdim M.B., Fridkin M., and Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech. Ageing Dev. 126 2 (2005) 317-326
30. Youdim M.B., Stephenson G., and Ben-Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, Desferal and VK-28. Ann. N.Y. Acad. Sci. 1012 (2004) 306-325
31. Zecca L., Youdim M.B., Riederer P., Connor J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5 11 (2004) 863-873
32. Zheng H., Gal S., Weiner L.M., Bar-Am O., Warshawsky A., Fridkin M., and Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95 1 (2005) 68-78